611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
Teens' Heart Risk From COVID Far Exceeds That of Vaccination: StudyCould COVID-19 Accelerate Alzheimer's Symptoms?New Data Details Dangers of Delta Variant, Even for the VaccinatedCDC Now Says Vaccinated Should Be Tested After COVID Exposure, Even Without SymptomsWhy Strokes Can Affect Women, Men DifferentlyMore Than Half of Americans Plagued by Back, Leg PainPfizer Says 3rd Shot of Vaccine Boosts COVID ProtectionVitamin D May Lower Black Women's Odds for COVID-19Primary Care Doctors Often Miss Heart Failure in Women, Black PatientsBogus Info on Cancer Common Online, and It Can HarmDelta Variant Spreads More Easily, Causing CDC Change on Indoor MaskingSevere COVID for People Under 45: Who's Most at Risk?The Heat Is On: Staying Safe When Temperatures SoarWho's Most Likely to Refuse a COVID Vaccine?Second COVID Shot Safe in Folks Who Had Allergic Reaction to FirstHigh Blood Pressure: Which Drug Works Best for You?Pfizer, Moderna to Expand Vaccine Studies in Young ChildrenFederal, State Moves Begin to Mandate COVID Vaccines for WorkersCan COVID Transmit Easily on Crowded School Buses?Worried About Delta-Linked 'Breakthrough' Infections? Experts Explain the RisksMajor Medical Groups Call for Mandatory COVID Vaccination for Health WorkersU.S. to Stick With International Travel RestrictionsSurvey Finds U.S. Parents Split on COVID Vaccination for Kids Under 12Most Unvaccinated Americans Want to Stay That Way: PollIt's Tick Season: Protect Yourself From Lyme DiseaseHigh-Tech Exoskeletons Improve Bowel Function in People With Spinal Cord Injury'Superbug' Fungus Spreads Among Vulnerable in Two U.S. CitiesVaccinations Start to Climb in States Hit Hard by Delta VariantAs Olympics Begin, Tokyo Posts Highest Number of New COVID Cases in Six MonthsVirtual Roller Coaster Ride Study Brings New Insights Into MigraineBiden Says Full Approval for COVID Vaccines Coming SoonPfizer Vaccine Offers 88% Protection Against Delta Variant, But 2 Doses NeededSecret Weapon: Why the 2nd Dose of Pfizer Vaccine Is So CrucialIn a First for the Continent, Pfizer COVID-19 Vaccine Will Be Produced in South AfricaLockdowns' Effects on Health Still Less Than Harm From Pandemic: ExpertsCOVID Drove Biggest Drop in U.S. Life Expectancy Since World War IIJ&J Vaccine Weak Against Delta Variant, 2nd Dose May Be NeededDouble Trouble: Wildfire Smoke Could Boost Odds for COVID's SpreadStatin Users May Have Added Protection Against Severe COVID-19Severe COVID in Kids: Rare, but Brain Issues Can ResultOne-Dose Blood Thinner Could Slash Blood Clot Risk After Knee ReplacementU.S. Issues Toughest Travel Alert for Britain As COVID Cases There ClimbPediatricians' Group: All School Kids, Staff Should Continue to Wear MasksGeneticists Probe Origins of Painful Cluster HeadachesAny COVID Infection Leaves Strong Antibody Levels in KidsMany Hit Hard by Pandemic Now Swamped by Medical DebtU.S. Surgeon General Backs Local Mask Mandates When NeededMake Summer Camp Safe for Your Child With Asthma, AllergiesCanada May Open Borders to Fully Vaccinated Americans by Mid-AugustCDC Advisors to Discuss 3rd COVID Vaccine Dose for Immunocompromised
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

A Better Test to Help Spot Glaucoma?

HealthDay News
by Ernie Mundell and Robert Preidt
Updated: Jul 16th 2021

new article illustration

FRIDAY, July 16, 2021 (HealthDay News) -- Glaucoma is a leading cause of vision loss in older people, and early detection can bring better treatment. Now, researchers in Australia say their experimental genetic test for glaucoma can identify 15 times more people at high risk for the disease compared to a current genetic test.

"Early diagnosis of glaucoma can lead to vision-saving treatment, and genetic information can potentially give us an edge in making early diagnoses and better treatment decisions," said lead researcher Owen Siggs in a news release from Flinders University. Siggs is associate professor at the university, as well as the Garvan Institute of Medical Research in Darlinghurst, New South Wales.

The new test analyzes blood or saliva samples and may be able to identify people at high risk for glaucoma before they suffer irreversible vision loss, the authors explained in a study published online July 15 in JAMA Ophthalmology.

One U.S. eye expert said the new screening method shows promise.

"Chronic open-angle glaucoma is a painless sight-threatening disease that often goes undetected until extensive visual damage has occurred," explained Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital in New York City. However, when detected and "treated early, visual loss can be limited," he added.

"Genetic testing is not currently used to detect glaucoma on a routine basis," Fromer said, but it "may be a valuable screening adjunct for the identification of many, but not all, patients with glaucoma. This new test has the potential to change the way we identify patients with glaucoma."

The new study involved more than 2,500 people in Australia with glaucoma, and more than 411,000 with or without glaucoma in the United Kingdom.

The findings show the potential of the new genetic test in glaucoma screening and management, according to study senior author Jamie Craig, a professor and consulting ophthalmologist who runs a glaucoma research program at Flinders University.

"We're now in a strong position to start testing this in clinical trials," Craig said in the news release.

Once glaucoma is diagnosed, there are several treatment options that can slow or halt the progression of vision loss, the study authors explained.

The research team members are forming a company to develop an accredited test for use in clinical trials, and recruitment is expected to begin in 2022.

More information

The U.S. National Eye Institute has more on glaucoma.

SOURCES: Mark Fromer, MD, ophthalmologist, Lenox Hill Hospital, New York City; Flinders University, news release, July 15, 2021